Hormone Therapy for Lung Cancer White Plains NY

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Local Companies

Montefiore Medical Center
718-920-4321
111 East 210th Street
Bronx, NY
Sound Shore Medical Center
914-632-5000
16 Guion Place
New Rochelle, NY
Helen Hayes Hospital
845-786-4000
Route 9w
West Haverstraw, NY
Mount Sinai Hospital Of Queens
718-932-1000
25-10 30th Avenue
Long Island City, NY
Summit Park Hospital
845-364-2700
50 Sanatorium Road
Pomona, NY
Blythedale Children'S Hospital
914-592-7555
95 Bradhurst Avenue
Valhalla, NY
Ny Westchester Square Med Ctr
718-430-7300
2475 St Raymond Avenue
Bronx, NY
Hudson Valley Hospital Center
914-737-9000
1980 Crompond Road
Cortlandt Manor, NY
North General Hospital
212-423-4000
1879 Madison Avenue
New York, NY
Select Specialty Hospital
201-221-2351
96 Parkway
Rochelle Park, NJ
Data Provided by:
  

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Prostate Cancer White Plains NY
Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.
- Breast Cancer Treatment White Plains NY
- Delayed Prostate Cancer Therapy White Plains NY
- Hormone Therapy White Plains NY
- Hormone Therapy for Early Prostate Cancer White Plains NY
- Hormone Therapy for Breast Cancer White Plains NY
- Head and Neck Cancer Treatment White Plains NY
- Drug Combo Proves Powerful Against Lung Cancer White Plains NY
- Menopausal Hormone Therapy White Plains NY